Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 126,500
- Avg volume
- 149,654
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 38%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and t...
Show more
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. The company was incorporated in 2002 and is based in Toronto, Canada.
- Industry
- Packaged Foods
- Sector
- Consumer Defensive
- Phone
- 888 376 8258
- Website
- https://www.psykeyworld.com
- Address
- 17 Belfield Road, Etobicoke, Toronto, Canada
Latest news
No headlines yet.
